Skip to main content
Signal8

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

$GILDPress releaseJun 24, 2026, 4:29 PM ETRead the release

The FDA approved Gilead's Trodelvy for first-line treatment of metastatic triple-negative breast cancer, expanding its use from later lines of therapy to the initial treatment setting. Approval was supported by Phase 3 data showing a 38% reduction in risk of disease progression or death as monotherapy and a 35% reduction when combined with Keytruda.

Key figures

Drug Name
Trodelvy (sacituzumab govitecan-hziy)
Phase Of Trial
Phase 3
Patients treated globally
75000
Pfs risk reduction ascent 03
38%
Pfs risk reduction ascent 04
35%
Duration of response ascent 03
12.2 months
Duration of response ascent 04
16.5 months
Trop2 expression in breast lung
>90%

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.